Full-Time
Head of PT Business IT OT Architecture & Standardization
Posted on 11/23/2025
Roche
1-10 employees
Global pharmaceuticals and diagnostics company
No salary listed
Oceanside, CA, USA + 3 more
More locations: Bellheim, Germany | Mississauga, ON, Canada | Garmisch-Partenkirchen, Germany
In Person
 Operations & Logistics (1) |
|---|
- 12+ years of progressive experience in ITOT architecture, digital transformation, or technology strategy roles within a complex, global manufacturing or technical operations environment, preferably in life sciences/pharma
- 7+ years of senior leadership experience, specifically building, developing, and leading multi-disciplinary and matrix teams
- Exceptional leadership skills with a demonstrated mastery of leading through influence, negotiating, and building consensus within a complex global matrix organization
- Proven track record of successfully standardizing technology stacks, designing and implementing complex industrial architectures, and driving simplification initiatives at scale
- Strong understanding of pharmaceutical regulatory requirements (e.g., GxP, data integrity, cybersecurity in OT) and experience ensuring compliance through architectural design
- Exceptional strategic thinking, analytical, and problem-solving capabilities, with the proven ability to translate complex technical challenges into clear strategic directions and actionable plans
- Superior communication, negotiation, and influencing skills, capable of engaging, aligning, and building consensus with diverse senior stakeholders across technical and business functions
- Translate business strategies into future technology requirements and ensure a state-of-the-art IT OT environment that supports critical business processes linked to clear business priorities and outcomes
- Provide strategic leadership for the design, development, and evolution of PT's future-proof Smart Manufacturing architecture, ensuring alignment with enterprise architecture principles and leading industry best practices
- Ensure PT's IT/OT landscape meets future business needs and be accountable for the standardization and simplification of PT's technology stack, driving efficiency, reducing complexity, and enhancing scalability across global operations in close partnership with ITOT and IT
- Own and drive the effectiveness and rigor of the Digital Data Backbone Capability Team within the Technology Portfolio Committee process, acting as the accountable owner for the new technology portfolio and champion the radical simplification and standardization of our current technology stack to reduce complexity, increase efficiency, and enable faster innovation
- Build, mentor, mobilize, and empower a high-performing, multi-disciplinary team of Business Architects, Business Analysts and Business Product Owners
- Masterfully navigate the complex stakeholder network across PT, global functions, ITOT, and IT leading through influence to build consensus and ensure strategic alignment, buy-in, and successful delivery of digital initiatives
- Foster a culture of continuous improvement, encouraging experimentation, learning from failures, and adapting to evolving technological landscapes
- Preferably in life sciences/pharma
Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.
Company Size
1-10
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1896
Simplify's Take
What believers are saying
- PathAI can strengthen AI pathology workflows and biomarker discovery.
- Elecsys pTau217 expands Roche's Alzheimer diagnostics beyond specialist laboratory settings.
- Nurix collaboration deepens Roche's reach into protein degradation and hematology.
What critics are saying
- Swiss franc strength keeps distorting reported growth and investor perception.
- Patent expirations on older medicines force rapid replacement from newer assets.
- CT-388 must beat Novo Nordisk and Eli Lilly to matter.
What makes Roche unique
- Roche combines pharmaceuticals, diagnostics, and digital pathology across one healthcare platform.
- Founded in Basel in 1896, Roche built scale through branded medicines.
- Genentech integration made Roche the world's largest biotechnology company.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Roche who can refer or advise you
Benefits
Performance Bonus
Company News
SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.
Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.
Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.
Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.
Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.